

Francesca Assogna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9247842/publications.pdf>

Version: 2024-02-01

64
papers

3,295
citations

172457

29
h-index

168389

53
g-index

68
all docs

68
docs citations

68
times ranked

6400
citing authors

#	ARTICLE	IF	CITATIONS
1	The <scp>ENIGMA</scp> Stroke Recovery Working Group: Big data neuroimaging to study brain-behavior relationships after stroke. <i>Human Brain Mapping</i> , 2022, 43, 129-148.	3.6	54
2	Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study. <i>Journal of Neural Transmission</i> , 2021, 128, 273-277.	2.8	19
3	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. <i>JAMA Psychiatry</i> , 2021, 78, 47.	11.0	136
4	Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. <i>Journal of Personalized Medicine</i> , 2021, 11, 51.	2.5	9
5	Effectiveness of a Family Support Intervention on Caregiving Burden in Family of Elderly Patients With Cognitive Decline After the COVID-19 Lockdown. <i>Frontiers in Psychiatry</i> , 2021, 12, 590104.	2.6	12
6	Immune System and Neuroinflammation in Idiopathic Parkinson's Disease: Association Analysis of Genetic Variants and miRNAs Interactions. <i>Frontiers in Genetics</i> , 2021, 12, 651971.	2.3	8
7	International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2583-2594.	3.9	54
8	Cerebellar GABA Levels and Cognitive Interference in Parkinson's disease and Healthy Comparators. <i>Journal of Personalized Medicine</i> , 2021, 11, 16.	2.5	6
9	Foot Pressure Wearable Sensors for Freezing of Gait Detection in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 128.	3.8	38
10	Mapping Cortical and Subcortical Asymmetry in Obsessive-Compulsive Disorder: Findings From the ENIGMA Consortium. <i>Biological Psychiatry</i> , 2020, 87, 1022-1034.	1.3	73
11	Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters. <i>Translational Psychiatry</i> , 2020, 10, 342.	4.8	43
12	Subclinical Cognitive and Neuropsychiatric Correlates and Hippocampal Volume Features of Brain White Matter Hyperintensity in Healthy People. <i>Journal of Personalized Medicine</i> , 2020, 10, 172.	2.5	7
13	Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. <i>NeuroImage</i> , 2020, 218, 116956.	4.2	135
14	Subcortical Brain Volume, Regional Cortical Thickness, and Cortical Surface Area Across Disorders: Findings From the ENIGMA ADHD, ASD, and OCD Working Groups. <i>American Journal of Psychiatry</i> , 2020, 177, 834-843.	7.2	120
15	Drug Choices and Advancements for Managing Depression in Parkinson's Disease. <i>Current Neuropharmacology</i> , 2020, 18, 277-287.	2.9	31
16	Feasibility and Utility of mHealth for the Remote Monitoring of Parkinson Disease: Ancillary Study of the PD_manager Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2020, 8, e16414.	3.7	33
17	Neurobiological Basis of Childhood Trauma and the Risk for Neurological Deficits Later in Life. , 2020, , 385-410.		2
18	Chronic Pain in the Elderly with Cognitive Decline: A Narrative Review. <i>Pain and Therapy</i> , 2019, 8, 53-65.	3.2	71

#	ARTICLE	IF	CITATIONS
19	Action Observation With Dual Task for Improving Cognitive Abilities in Parkinson's Disease: A Pilot Study. <i>Frontiers in Systems Neuroscience</i> , 2019, 13, 7.	2.5	11
20	Gender specific decrease of a set of circulating N-acylphosphatidyl ethanolamines (NAPEs) in the plasma of Parkinson's disease patients. <i>Metabolomics</i> , 2019, 15, 74.	3.0	9
21	Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study. <i>Neurological Sciences</i> , 2019, 40, 1377-1382.	1.9	27
22	Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism. <i>Brain and Behavior</i> , 2019, 9, e01448.	2.2	9
23	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. <i>Biological Psychiatry</i> , 2019, 85, e35-e39.	1.3	5
24	Elevated plasma ceramide levels in post-menopausal women: a cross-sectional study. <i>Aging</i> , 2019, 11, 73-88.	3.1	36
25	Orthostatic hypotension acutely impairs executive functions in Parkinson's disease. <i>Neurological Sciences</i> , 2018, 39, 1459-1462.	1.9	10
26	Anosognosia for cognitive and behavioral symptoms in Parkinson's disease with mild dementia and mild cognitive impairment: Frequency and neuropsychological/neuropsychiatric correlates. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 62-67.	2.2	32
27	Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study. <i>Neurological Sciences</i> , 2018, 39, 141-143.	1.9	10
28	Anti-inflammatory Effects of Homotaurine in Patients With Amnesic Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 285.	3.4	14
29	Psychiatric profile of motor subtypes of de novo drug-naïve Parkinson's disease patients. <i>Brain and Behavior</i> , 2018, 8, e01094.	2.2	4
30	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. <i>Biological Psychiatry</i> , 2018, 84, 644-654.	1.3	627
31	Influence of APOE and RNF219 on Behavioral and Cognitive Features of Female Patients Affected by Mild Cognitive Impairment or Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 92.	3.4	8
32	Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 50-56.	2.2	31
33	Dopaminergic system and dream recall: An MRI study in Parkinson's disease patients. <i>Human Brain Mapping</i> , 2016, 37, 1136-1147.	3.6	36
34	Alexithymia in Parkinson's disease: A systematic review of the literature. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 1-11.	2.2	41
35	Unraveling predictors affecting compliance to MRI in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 964-967.	2.2	2
36	Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson's disease. <i>European Neuropsychopharmacology</i> , 2015, 25, 69-76.	0.7	35

#	ARTICLE	IF	CITATIONS
37	Neuropsychiatric and cognitive symptoms and body side of onset of parkinsonism in unmedicated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1096-1100.	2.2	36
38	On the relationship between side of onset and cognition in Parkinson disease: Response from the authors. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1481-1482.	2.2	1
39	Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. <i>Molecular Psychiatry</i> , 2014, 19, 1143-1149.	7.9	293
40	The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 1126-1132.	3.6	14
41	Polygenic determinants of white matter volume derived from GWAS lack reproducibility in a replicate sample. <i>Translational Psychiatry</i> , 2014, 4, e362-e362.	4.8	35
42	Does a volume reduction of the parietal lobe contribute to freezing of gait in Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1101-1103.	2.2	36
43	Anhedonia in Parkinson's Disease and Other Movement Disorders. , 2014, , 265-290.		0
44	Increased expression of Interleukin-18 receptor in blood cells of subjects with Mild Cognitive Impairment and Alzheimer's disease. <i>Cytokine</i> , 2013, 61, 360-363.	3.2	12
45	HEDONIC TONE AND ITS MOOD AND COGNITIVE CORRELATES IN PARKINSON'S DISEASE. <i>Depression and Anxiety</i> , 2013, 30, 85-91.	4.1	11
46	Rotigotine for anxiety during wearing-off in Parkinson's disease with dementia. <i>Aging Clinical and Experimental Research</i> , 2013, 25, 601-603.	2.9	9
47	Depressive symptoms in Parkinson's disease and in non-neurological medical illnesses. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 389.	2.2	8
48	Blood Dendritic Cell Frequency Declines in Idiopathic Parkinson's Disease and Is Associated with Motor Symptom Severity. <i>PLoS ONE</i> , 2013, 8, e65352.	2.5	38
49	Effects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer's and Parkinson's diseases. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 37.	3.4	30
50	Hippocampal abnormalities and memory deficits in Parkinson disease. <i>Neurology</i> , 2012, 78, 1939-1945.	1.1	123
51	Alexithymia in Parkinson's disease: secondary phenomenon or primary neuropsychiatric feature?. <i>Neurodegenerative Disease Management</i> , 2012, 2, 343-346.	2.2	3
52	Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 871-875.	2.2	23
53	Alexithymia Is a Non-Motor Symptom of Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 133-141.	1.2	38
54	Regional cortical thickness and cognitive functions in non-demented Parkinson's disease patients: a pilot study. <i>European Journal of Neurology</i> , 2012, 19, 172-175.	3.3	26

#	ARTICLE	IF	CITATIONS
55	Dysbindin CÁA&T haplotype is associated with thicker medial orbitofrontal cortex in healthy population. <i>NeuroImage</i> , 2011, 55, 508-513.	4.2	12
56	MAO A VNTR polymorphism and amygdala volume in healthy subjects. <i>Psychiatry Research - Neuroimaging</i> , 2011, 191, 87-91.	1.8	18
57	Anhedonia in Parkinson's disease: A systematic review of the literature. <i>Movement Disorders</i> , 2011, 26, 1825-1834.	3.9	60
58	The neuropsychological correlates of cognitive insight in healthy participants. <i>Applied Cognitive Psychology</i> , 2011, 25, 927-932.	1.6	18
59	Amygdala and hippocampus volumetry and diffusivity in relation to dreaming. <i>Human Brain Mapping</i> , 2011, 32, 1458-1470.	3.6	67
60	Intensity-dependent facial emotion recognition and cognitive functions in Parkinson&TM's disease. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 867-876.	1.8	49
61	Magnetic resonance imaging markers of Parkinson&TM's disease nigrostriatal signature. <i>Brain</i> , 2010, 133, 3423-3433.	7.6	374
62	Morphological correlates of MAO A VNTR polymorphism: New evidence from cortical thickness measurement. <i>Behavioural Brain Research</i> , 2010, 211, 118-124.	2.2	27
63	Met158 variant of the catechol-O-methyltransferase genotype is associated with thicker cortex in adult brain. <i>Neuroscience</i> , 2010, 167, 809-814.	2.3	32
64	The recognition of facial emotion expressions in Parkinson's disease. <i>European Neuropsychopharmacology</i> , 2008, 18, 835-848.	0.7	97